Actively Recruiting
Long-Term Safety Monitoring of Lecanemab-irmb Treatment in Alzheimers Disease Using the ALZ-NET Registry
Led by Eisai Inc. · Updated on 2026-09-16
6700
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety of lecanemab-irmb in people with Alzheimers Disease in real-world clinical settings. The study focuses on monitoring specific adverse events related to amyloid-related imaging abnormalities such as edema and hemosiderin deposits, as well as other serious events like seizures, anaphylaxis, ischemic events in the central nervous system, and intracerebral hemorrhage. It also compares safety outcomes among participants with different baseline features and prior treatments. Participants prescribed lecanemab-irmb by their physicians as part of routine care will be observed through the ALZ-NET registry, which collects data from about 20,000 patients, including around 6,700 treated with lecanemab-irmb. This is a non-interventional study, meaning participants receive standard care without additional treatments assigned by the study. The safety of lecanemab-irmb will be assessed over up to 10 years using registry data. During the study, researchers will review reports of adverse events and exposures to lecanemab-irmb, focusing on imaging abnormalities and other serious health events. They will analyze risks related to genetic factors, prior Alzheimers treatments, and antithrombotic use. Data collection occurs continuously within the registry, allowing long-term monitoring of participants safety outcomes. The study runs from May 2025 through January 2035.
CONDITIONS
Brief Title
A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease
Research Team
E
Eisai Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here